Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide vs Insulin Glargine in T2DM Inadequately Controlled on Metformin and Sulfonylurea
NCT01051011Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2010
- Primary completion
- Dec 2010
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of taspoglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Roche. Primary endpoint: Glycemic control assessed by HbA1c at 24 weeks. Started Jan 2010; status: terminated.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01051011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051011.